COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy of Zinc in Reducing Hyperbilirubinemia Among High Risk Neonates - A Double Blind Randomized Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00692224
Recruitment Status : Completed
First Posted : June 6, 2008
Last Update Posted : June 6, 2008
Information provided by:
All India Institute of Medical Sciences, New Delhi

Brief Summary:
The purpose of this study is to determine the effect of 10 mg of oral zinc given daily between days 2 and 7 of life to term or near term neonates with serum bilirubin levels of more than 6 mg/dL at 24 ± 6 hours of life on hyperbilirubinemia and phototherapy.

Condition or disease Intervention/treatment Phase
Neonatal Jaundice Drug: zinc gluconate Drug: placebo Phase 1 Phase 2

Detailed Description:

Neonatal hyperbilirubinemia is a common problem occurring in nearly 5-25% neonates.Inhibition of enterohepatic circulation is one of the therapies being tried for neonatal jaundice. Studies have suggested that in a neonate, the postulated enterohepatic pathway is of a magnitude that could be significant in the overall body economy of bilirubin.Zinc has also been investigated for its role in decreasing the STB levels by inhibiting enterohepatic circulation. There have been animal studies which have investigated the role of zinc in decreasing the serum bilirubin levels. The mechanism proposed is that zinc salts precipitate Unconjugated bilirubin from unsaturated micellar solution of bile salts and consequently inhibit the enterohepatic circulation of bilirubin. This is the first study to evaluate the role of zinc in neonatal jaundice.

Study Design: In this randomized placebo controlled clinical trial neonates born at ≥35 wk of gestation and with total serum bilirubin ≥6mg% were given either zinc gluconate (n = 148) or placebo (n = 146) in a dose of 10mg per day between days 2 and 7 of life. Jaundice was assessed clinically and total serum bilirubin estimated using spectrophotometry. Infants were followed up clinically until discharge and then again at day 7 of life. Hyperbilirubinemia was defined as total serum bilirubin ≥15mg%.

Results: Incidence of hyperbilirubinemia was comparable in zinc and placebo groups (OR 0.95, 95% CI 0.50-1.67, p=0.92). The requirement of phototherapy was similar in the two groups (OR 0.81, 95% CI 0.41-1.61, p=0.55). The mean hours of phototherapy in the zinc group were also similar in the two groups (p=0.63). No significant difference with respect to mean levels of bilirubin (mg/dL) at 72±12 hours of age was observed in two groups(zinc 11.3±3.3,placebo 11.5±3.8,p=0.63). No significant adverse effects of zinc were noted.

Conclusion: Twice daily zinc administration in a dose of 10 mg/day does not reduce hyperbilirubinemia in at risk neonates in the first week of life.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 294 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Effect of Oral Zinc Given Daily Between Days 2 and 7 of Life to Term or Near Term Neonates With Serum Bilirubin Levels of More Than 6 mg/dL at 24 ± 6 Hours of Life on Hyperbilirubinemia and Phototherapy
Study Start Date : October 2005
Actual Primary Completion Date : October 2006
Actual Study Completion Date : October 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Jaundice

Arm Intervention/treatment
Active Comparator: 1
study group received zinc gluconate in a dose of 10 mg/day
Drug: zinc gluconate
zinc gluconate syrup - 10mg/day in two divided doses from day 2 to day 7 of life

Placebo Comparator: 2
placebo group received placebo which was identical in color, taste and appearance and packaged in similar looking bottles.
Drug: placebo
placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug

Primary Outcome Measures :
  1. Incidence of hyperbilirubinemia defined as total serum bilirubin more than or equal to 15 mg/dL at anytime between days 2 and 7 of life. [ Time Frame: first week of life ]

Secondary Outcome Measures :
  1. The mean total serum bilirubin level at 72±12 hours of age. [ Time Frame: first two weeks of life ]
  2. The proportion of infants requiring phototherapy and the duration thereof [ Time Frame: first two weeks of life ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 30 Hours   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Neonates born at ≥35 weeks gestation and with total serum bilirubin ≥ 6 mg/dL at 24±6 h of life.

Exclusion Criteria:

  • Rh incompatibility
  • Those given exchange transfusion/ phototherapy within 24 h of age.
  • Major gross congenital anomaly
  • Anticipated to require neonatal intensive care or required neonatal intensive care for more than 24 h.
  • Systemic sepsis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00692224

Layout table for location information
All India Institute Of Medical Sciences
New Delhi, Delhi, India, 110029
Sponsors and Collaborators
All India Institute of Medical Sciences, New Delhi
Layout table for investigator information
Principal Investigator: Nidhi Rana, M.D All India Institute of Medical Sciences, New Delhi
Layout table for additonal information
Responsible Party: Nidhi Rana, All India Institute of medical sciences Identifier: NCT00692224    
Other Study ID Numbers: A-68:12/08/2005
First Posted: June 6, 2008    Key Record Dates
Last Update Posted: June 6, 2008
Last Verified: June 2008
Keywords provided by All India Institute of Medical Sciences, New Delhi:
neonatal jaundice
enterohepatic circulation
Additional relevant MeSH terms:
Layout table for MeSH terms
Jaundice, Neonatal
Pathologic Processes
Skin Manifestations
Hyperbilirubinemia, Neonatal
Infant, Newborn, Diseases